ARTICLE | Company News
Bio3 Research, Protelica deal
July 5, 2010 7:00 AM UTC
Bio3 exercised an option to license exclusive rights to the preclinical high mobility group box 1 (HMGB1) antagonists that the companies were co-developing under a 2008 deal to treat cardiovascular d...